Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.

已完结 10 由 Luke 发布于 2025/11/27 13:28:48

DOI:10.1056/nejmoa2503001
作者：James Chih-Hsin Yang,Shun Lu,Hidetoshi Hayashi,Enriqueta Felip,Alexander I Spira,Nicolas Girard,Yu Jung Kim,Se-Hoon Lee,Yurii Ostapenko,Pongwut Danchaivijitr,Baogang Liu,Adlinda Alip,Ernesto Korbenfel
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：BACKGROUND Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)-mutated advanc

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Wiley2‐Amino‐6‐hydroxypyrimidine‐4(3H)‐one